بإذنك، نستخدم تحليلات محدودة تراعي الخصوصية لفهم مسارات البحث الفعالة. لا نستخدم أدوات تتبع إعلانية أو تسجيل الجلسات. يمكنك تغيير هذا الخيار في التفضيلات. اقرأ سياسة الخصوصية.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
MO — frequently asked questions
Is Altria Group, Inc. overvalued?
In our latest published analysis dated 2026-10-18, MO looks meaningfully overvalued. The price recorded at analysis is 75.1 USD versus our fair value of 61.6 USD; the high endpoint is presented separately as potential value of 84.6 USD. That implies roughly 18.0% downside to fair value at that date.
Our latest published report, analyzed 2026-10-18, gives MO a fair value of 61.6 USD and a potential value of 84.6 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Altria Group, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy MO now?
Our latest published rating for MO, analyzed 2026-10-18, is Reduce. Altria Group, Inc. looks meaningfully overvalued at the analysis-date price of 75.1 USD versus fair value of 61.6 USD; potential value is 84.6 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for MO?
The dedicated bear-case section in our report analyzed 2026-10-18 documents Altria Group, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is MO's rating?
Our latest published rating for MO, analyzed 2026-10-18, is Reduce, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of 61.6 USD, the potential value of 84.6 USD, and the price recorded at analysis (75.1 USD).
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذيEN
الإجابة في 30 ثانيةReduce
السعر مقابل القيمة
Price
$75.11
Fair value
$61.61
Potential value
$84.57
As of
2026-10-16
لماذا قد تنجح الفرضية
The primary upside opportunity lies in Altria's commercial expansion of on!
ما الذي سيغيّر تقييمنا
Domestic cigarette shipment volume contraction accelerates beyond 8.0% year-over-year, driven by potential FDA regulatory actions such as product standards banning menthol in cigarettes or consumer price elasticity breaking after repeated ~7% annual Marlboro price hikes.
Altria Group Inc. (MO) is maintained at a Reduce rating as current trading levels ($75.11 as of October 16, 2026) reflect a 21.9% price premium over mid intrinsic fair value of $61.61, leaving investors with an implied return of -18.0%. While Marlboro pricing power continues to sustain near-term cash generation, secular combustible cigarette volume contraction (-4.5% trade-adjusted in Q2 2026), consumer trade-down into discount brands (33.8% category share), and execution roadblocks in modern smoke-free platforms create an unfavorable risk/reward profile.3,4
Altria Group Inc. presents a fundamental conflict between world-class cash extraction in a declining legacy business and structural vulnerability in future nicotine categories. Operating income in FY2025 reached $9,899M on net of $23,279M, generating $9,074M in after just $216M in . This cash engine is driven almost entirely by Philip Morris USA, whose flagship Marlboro brand commands 59.6% of the U.S. premium cigarette segment. By raising Marlboro retail prices ~7% annually against an inelastic demand coefficient of -0.35, management expanded Smokeable adjusted OCI margins to 64.9% in H1 2026, supporting $3.9B in dividends and buybacks across the first six months of 2026.
However, this pricing umbrella is encountering structural stress. In Q2 2026, reported domestic cigarette shipment volume declined 3.2% (4.5% adjusted for trade inventories), with Marlboro volume contracting 7.4%. Persistent macroeconomic inflation has pressured lower-income adult consumers to trade down, driving discount cigarette category share up 2.6 percentage points to 33.8%. While PM USA has expanded Marlboro Cowboy Cut and Basic to capture value-sensitive smokers, product mix is progressively diluting net revenue realization. Furthermore, the company relies heavily on two wholesale distributors who account for 42% of consolidated net revenues.4
Altria's strategic transition toward smoke-free platforms has not scaled rapidly enough to offset the combustible decline. While Helix has expanded on! PLUS to 120,000 stores, on! captured only 14.4% of the nicotine pouch category in Q2 2026, down 1.7 percentage points year-over-year. In e-vapor, NJOY ACE remains barred from importation in 2026 under ITC exclusion orders, leaving Altria without a commercial presence in modern vapor following an $873M goodwill impairment in 2025. Meanwhile, illicit disposable vapes continue to siphon adult nicotine consumers away from authorized retail channels.4
At $75.11 (as of 2026-10-16), Altria shares trade above Fair value ($61.61), offering -18.0% implied upside toward the midpoint. With negative stockholders' equity and substantial total debt, the valuation provides little margin of safety against regulatory shocks or continued trade-down into discount cigarette categories.
Marlboro maintained a 59.6% share of the U.S. premium cigarette segment and 39.5% total cigarette category retail share in Q2 2026. This pricing power enabled Philip Morris USA to lift Marlboro retail prices by ~7% YoY in Q2 2026 while maintaining a stable -0.35 price elasticity coefficient, expanding Smokeable segment adjusted OCI margins to 64.8% in Q2 2026 and 64.9% in H1 2026.4
Regulatory Scale and Direct Route-to-Market Distribution
Altria operates an entrenched nationwide distribution network reaching over 120,000 retail locations for on! PLUS, supported by long-term Master Settlement Agreement compliance infrastructure and wholesale contracts. In FY2025, two premier wholesale distributors accounted for 23% and 19% of consolidated net revenues, respectively. Stringent FDA marketing restrictions and retail display contracts create prohibitive barriers to entry for potential new combustible cigarette competitors.
Cycle upside
A favorable cycle scenario entails recovering consumer discretionary purchasing power, moderating combustible cigarette volume contraction toward low-single-digit rates annually, and strict FDA enforcement against illicit disposable vapes that redirects volume back into authorized combustible brands and modern nicotine pouches. Under these conditions, premium brand equity remains fully intact, price realization easily compensates for volume decline, and modern oral pouch platforms experience rapid adoption across nationwide convenience and grocery store networks.
توصية الدار
Reduce. Altria's near-term dividend yield (~5.9%) and robust free cash flow ($9.07B in FY2025) are overextended at $75.11, trading 21.9% above mid fair value ($61.61). Compounding cigarette volume losses (-4.5% trade-adjusted in Q2 2026), discount category expansion to 33.8%, and smoke-free execution roadblocks leave the stock vulnerable to terminal multiple de-rating.3,4,5
نظرة عامة على الشركة
Altria Group, Inc. is a leading U.S. consumer defensive manufacturer specializing in combustible tobacco and smoke-free nicotine products for adult consumers aged 21 and older. Its wholly owned operating companies include Philip Morris USA Inc. (PM USA), the manufacturer of Marlboro cigarettes; John Middleton Co., a leading domestic machine-made cigar manufacturer; U.S. Smokeless Tobacco Company LLC (USSTC), the leading producer of moist smokeless tobacco including Copenhagen and Skoal; Helix Innovations LLC, manufacturer of on! oral nicotine pouches; and NJOY, LLC, an e-vapor manufacturer with marketing granted orders from the FDA. Altria also holds a majority-owned joint venture, Horizon Innovations LLC, for heated tobacco products, as well as significant equity investments in Anheuser-Busch InBev SA/NV (ABI) and Cronos Group Inc..
The company reports through two primary operating segments: Smokeable Products and Oral Tobacco Products, alongside an All Other category that includes NJOY and novel platforms. In FY2025, Smokeable Products generated $20,485M in net revenues and $10,984M in operating companies income, while Oral Tobacco delivered $2,802M in revenues and $1,828M in operating income. Sales are concentrated domestically, with two wholesale distributors accounting for 23% and 19% of consolidated net revenues in FY2025, respectively.
§2 السيناريو الهبوطيEN
A stress test combining combustible volume contraction beyond 8.0% YoY, discount cigarette market share expansion above 35%, and multiple de-rating to 9.0x forward earnings severely challenges Altria's capital structure and shareholder return model. Altria carries $24,577M in total debt and negative stockholders' equity of -$2,668M as of June 30, 2026 following years of debt-funded share repurchases and progressive dividends. While Altria generated $9,290M in operating cash flow and $9,074M in free cash flow in FY2025, dividend commitments require ~$7.2B annualized ($3.6B paid in H1 2026). Historically, management retains only ~$1.0B in excess cash flow after dividends. A 15-20% contraction in Smokeable segment operating income ($10,984M in FY2025) would eliminate discretionary free cash flow, halt share repurchases ($335M in H1 2026), and strain investment in smoke-free manufacturing platforms ($375M-$450M guided 2026 CapEx). Under higher refinancing rates on its $24.58B debt load, interest coverage would deteriorate rapidly.
Consolidated operating margin drops below 39.5% under expanded promotional allowances
كيف يمكن أن تفشل هذه الأطروحة
FDA menthol cigarette ban implementation and accelerated combustible volume contraction
In Q2 2026, reported domestic cigarette shipment volume declined 3.2% (4.5% adjusted for trade inventories) with Marlboro down 7.4%. If the FDA finalizes product standards banning menthol in cigarettes, Altria's combustible volume losses would accelerate beyond 8% YoY, eliminating the ability of pricing realization to offset volume loss and impairing smokeable operating income ($10,984M in FY2025), inducing an estimated -24.5% fair value shock.4,7
FV impact
-8.2%
Revenue and EPS growth 5 points lower for five years
Trigger
إشارات الإنذار المبكر للمراقبة
التطورات الخمسة التي قد تضعف أطروحتنا الاستثمارية.
01
Domestic Cigarette Shipment Volume Decline
Accelerating combustible volume losses would overwhelm annual price realization (~7% Marlboro price increases), causing Smokeable segment operating income ($10,984M in FY2025) to contract in absolute dollars.
الحالي:-3.2% reported (-4.5% trade-adjusted) YoY in Q2 2026
Altria's wide economic moat is anchored by Marlboro, an iconic American consumer brand that has dominated U.S. combustible tobacco for over four decades. In Q2 2026, Marlboro accounted for 59.6% of the domestic premium cigarette category and 39.5% of total cigarette retail sales. This entrenched brand equity confers extraordinary pricing power, allowing PM USA to implement compounding ~7% annual retail price increases. Because adult cigarette demand exhibits inelastic behavior with a stable -0.35 elasticity coefficient, pricing realization has systematically outpaced volume declines, sustaining Smokeable operating companies income of $10,984M in FY2025 and generating H1 2026 adjusted OCI margins of 64.9%.
Beyond brand equity, Altria is protected by formidable regulatory barriers to entry. Strict marketing bans under the Master Settlement Agreement and comprehensive FDA regulatory oversight prevent new entrants from advertising or scaling competing combustible products. Altria's commercial scale leverages deeply integrated wholesale and retail partnerships, with two core wholesale distributors accounting for 23% and 19% of consolidated net revenue in FY2025. This route-to-market advantage provides retail shelf placement that competitors cannot replicate, enabling the distribution of on! PLUS across 120,000 stores nationwide.
Nevertheless, the moat's durability is narrowing due to secular shifts in nicotine consumption. Combustible volume is declining at 4-5% annually as consumers migrate toward modern oral pouches and e-vapor products. In these transition categories, Altria lacks pricing dominance. Helix's on! captured only 14.4% of pouch volume in Q2 2026, and NJOY ACE remains absent from the marketplace following ITC exclusion orders. Consequently, while current economic profits remain massive, the long-term terminal durability of Altria's moat faces structural degradation.
الربح الاقتصادي
Altria extracts substantial economic profits from its core tobacco franchises. Consolidated operating income reached $9,899M on $23,279M of net revenues in FY2025, generating an operating margin of 42.52%. Because capital expenditures were only $216M in FY2025 and reinvestment requirements track at ~2.0% of NOPAT, returns on tangible invested capital vastly exceed the company's computed WACC of 6.97% and moderate cost of equity of 7.46%. However, reported stockholders' equity is negative (-$2,668M as of June 30, 2026) due to extensive debt-funded capital distributions, so economic profit durability depends entirely on sustaining smokeable pricing realization against volume declines.2,6
7.5/ 10
Narrow
Sources of advantage
01Brand Equity and Combustible Pricing Power — Marlboro maintained a 59.6% share of the U.S. premium cigarette segment and 39.5% total cigarette category retail share in Q2 2026. This pricing power enabled Philip Morris USA to lift Marlboro retail prices by ~7% YoY in Q2 2026 while maintaining a stable -0.35 price elasticity coefficient, expanding Smokeable segment adjusted OCI margins to 64.8% in Q2 2026 and 64.9% in H1 2026.Wide
02Regulatory Scale and Direct Route-to-Market Distribution — Altria operates an entrenched nationwide distribution network reaching over 120,000 retail locations for on! PLUS, supported by long-term Master Settlement Agreement compliance infrastructure and wholesale contracts. In FY2025, two premier wholesale distributors accounted for 23% and 19% of consolidated net revenues, respectively. Stringent FDA marketing restrictions and retail display contracts create prohibitive barriers to entry for potential new combustible cigarette competitors.
التهديدات المعروفة للميزة التنافسية
التهديد
الخطورة
الجدول الزمني
التخفيف
Cross-category substitution into illicit disposable e-vapor products and modern nicotine pouches eroding combustible volume
high
Ongoing (1 to 3 years)
Expanding on! PLUS distribution to 120,000 stores, rolling out 12mg strengths and new flavors, and advocating for aggressive FDA enforcement against illicit disposable vapes.4
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
§5 الحساسية
معدل الخصم
النمو النهائي
1.0%
1.3%
1.5%
1.8%
2.0%
6.5%
$66.69
$68.46
$70.43
$72.65
$75.16
7.0%
$62.62
$64.04
$65.60
$67.34
$69.28
7.5%
$59.19
$60.35
$61.61
$63.00
$64.54
8.0%
$56.24
$57.20
$58.25
$59.38
$60.63
8.5%
$53.68
$54.49
$55.36
$56.30
$57.33
الصفوف: معدل الخصم (Ke للأرباح؛ WACC للتدفقات النقدية). الأعمدة: النمو النهائي.
تغير المدة (سنوات)
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
مرجع الحساسية
The highlighted cell is Fair value when every assumption sits at its base level ($61.61). Each row and column shows what Fair value becomes when one assumption moves.
منحدر التدفق النقدي الحر
Free cash flow to the firm stays positive in the first projected year at $7.6B after modeled reinvestment of $155.6M, with terminal value at 78.8% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Cost of capital moderate Ke remains at 7.46% and WACC at 6.97%
The Base scenario reflects the modal operating path: combustible volume secular decline is successfully mitigated by disciplined, continuous price realization. Marlboro maintains premium dominance while discount brands like Basic capture trade-down smokers. Smoke-free progress is modest, with on! growing absolute volume but losing pouch category share to dominant competitors, and NJOY remaining sidelined. Operating cash flow remains robust around $9.0B-$9.5B, enabling steady dividend payments ($4.44 per share) and modest share buybacks. However, with market price ($75.11) exceeding mid fair value ($61.61), investor returns are constrained.
Modern oral products on! and on! PLUS capture expanding share of the nicotine pouch market.
§7 شجرة قرارات الأرباحEN
تجاوز
Maintain Reduce; Maintain current portfolio allocations and evaluate whether earnings upside is driven by durable organic volume stabilization rather than one-off export duty credits or transient promotional pullbacks. Re-examine discount category penetration and on! PLUS distribution milestones before altering exposure.
A single-quarter earnings beat driven by pricing realization or timing benefits on cigarette import and export credits does not resolve multi-year combustible volume contraction (-4.5% trade-adjusted in Q2 2026) or justify the current 21.9% valuation premium over mid fair value ($61.61).
متوافق
Maintain Reduce; Continue systematic reduction of equity exposure into share price strength. Re-examine quarterly smokeable adjusted OCI margins and dividend coverage ratios to ensure capital return durability.
المُحفِّز: Quarterly adjusted diluted EPS within ±1% of consensus ($1.37 quarterly consensus) and full-year guidance affirmed between $5.61 and $5.72.4
Results matching consensus confirm the mature, slow-growth cash extraction trajectory modeled in our baseline forecast (revenue growth of 0.5% to 1.2% and EPS of $5.68 in FY2026), leaving current market prices ($75.11) substantially overextended relative to intrinsic value.
دون التوقعات
Downgrade the rating; Accelerate complete liquidation of remaining equity holdings, reallocating capital to defensive consumer staples with verifiable volume expansion and positive pricing power.
A quarterly earnings miss would signal an elasticity break in Marlboro pricing power or accelerated discount trade-down by adult smokers, impairing smokeable operating income and pushing equity value below Fair value.
جودة الأرباح
Altria exhibits clean underlying cash flow conversion but significant divergence between GAAP and non-GAAP earnings due to recurring special items. In FY2025, reported GAAP diluted EPS was $4.12 while adjusted diluted EPS was $5.42, reflecting $1,921M in after-tax asset impairment charges ($0.53/share non-cash goodwill impairment in e-vapor) and $110M in intangible amortization. In H1 2026, reported diluted EPS rose 30.9% to $2.67 while adjusted diluted EPS grew 4.9% to $2.80, reconciling across $94M in pre-tax restructuring costs for the USSTC facility consolidation, $97M in litigation charges, and $78M in ABI-related losses. Operating cash flow of $9,290M in FY2025 easily covered reported net income of $6,947M, confirming high core cash conversion despite portfolio write-downs.6
زخم التقديرات
Consensus earnings estimates have demonstrated exceptional stability following Q2 2026 results. Full-year FY2026 consensus diluted EPS is $5.68, aligning squarely within management's narrowed guidance range of $5.61 to $5.72. FY2027 EPS consensus stands at $5.86 on revenue of $20,717M. Material post-earnings revisions have recorded 0% change across major consensus trackers, reflecting broad agreement on Altria's steady cash extraction profile.1,4
المقاييس التي يجب مراقبتها قبل الإعلان
01
المقياس:
Marlboro Total Category and Premium Retail Share
الحالي39.5% total cigarette share (down 1.5 pp YoY); 59.6% premium segment share (flat YoY) in Q2 2026
لماذا يهم
Determines whether ongoing retail price hikes can continue without breaking brand equity and triggering premium volume erosion.
02
المقياس:
Discount Cigarette Industry Retail Share
الحالي33.8% of domestic cigarette sales in Q2 2026, up 2.6 percentage points YoY
لماذا يهم
Monitors adult smoker discretionary income strain and consumer trade-down, which dilutes consolidated margin mix.
Cash flow generation remains Altria's primary investment attribute. Operating cash flow reached $9,290M in FY2025, delivering free cash flow of $9,074M after deducting $216M of CapEx. Cash conversion from FY2025 operating income ($9,899M) was 93.8%, demonstrating minimal working capital drag and negligible capital intensity. However, cash flow stability is highly reliant on two wholesale customers who generated 42% of FY2025 net revenue (23% and 19%). As long as combustible pricing realization (~7% Marlboro price increases) offsets volume drops (-4.5% adjusted in Q2 2026), cash flow remains steady, but cushion beyond dividend payments is narrow.4
Altria operates with negative reported stockholders' equity (-$2,668M as of June 30, 2026; -$3,502M at year-end 2025) resulting from cumulative debt-funded share repurchases and regular dividend payouts exceeding historical retained earnings. Consequently, traditional accounting ROE is not meaningful. When measured against tangible invested capital, Altria's return on capital is high, driven by smokeable adjusted OCI margins of 64.9% in H1 2026. However, economic rent generation is in structural decline as combustible volume falls 4-5% annually and modern smoke-free platforms dilute enterprise margin mix.
Tangible return on invested capital significantly exceeds Altria's computed WACC of 6.97%, generating vast positive economic spread today. However, terminal value growth is constrained to 1.5% due to secular combustible volume contraction.
Extreme earnings concentration in combustible cigarettes subventions nascent smoke-free segments.
In FY2025, Smokeable Products delivered $10,984M of operating income on $20,485M , while Oral Tobacco generated $1,828M OCI on $2,802M revenue, and All Other produced an operating loss of -$229M.
أحدث إيرادات23.3 مليار US$معدل النمو السنوي المركب للإيرادات −1.1%
هامش التشغيل42.5%10 فترات مالية
أحدث تدفق نقدي حر9.1 مليار US$FY2025
صافي الدين21.2 مليار US$FY2025
تفصيل قائمة الدخلكيف يتحول حجم الأعمال إلى أرباح مُعلنة.
StockMarketAgent.AI
الإيرادات23.3 مليار US$تكلفة الإيرادات−8.7 مليار US$إجمالي الربح14.5 مليار US$المصروفات التشغيلية−4.6 مليار US$الدخل التشغيلي9.9 مليار US$البنود غير التشغيلية والضرائب−3 مليار US$صافي الدخل6.9 مليار US$
بيانات التاريخ المالي
الإيرادات
23,279,000,000 US$
تكلفة الإيرادات
8,737,000,000 US$
إجمالي الربح
14,542,000,000 US$
المصروفات التشغيلية
4,643,000,000 US$
الدخل التشغيلي
9,899,000,000 US$
البنود غير التشغيلية والضرائب
-2,952,000,000 US$
صافي الدخل
6,947,000,000 US$
لمحة عن الميزانية العموميةكيفية الاحتفاظ بالأصول المُبلغ عنها وتمويلها في الفترة المحددة.
StockMarketAgent.AI
تكوين الأصولمصادر التمويل
إجمالي الأصول35 مليار US$النقد4.5 مليار US$الأصول المتداولة5.9 مليار US$إجمالي الالتزامات38.5 مليار US$الالتزامات المتداولة9.2 مليار US$عجز حقوق المساهمين3.5 مليار US$
بيانات تفصيل الميزانية العمومية
إجمالي الأصول
35,017,000,000 US$
النقد
4,474,000,000 US$
الأصول المتداولة
5,932,000,000 US$
إجمالي الالتزامات
38,469,000,000 US$
الالتزامات المتداولة
9,154,000,000 US$
عجز حقوق المساهمين
3,452,000,000 US$
جسر التدفق النقديكيف تحول التدفق النقدي التشغيلي إلى تدفق نقدي حر في FY2025.
StockMarketAgent.AI
تسوية التدفق النقدي التشغيلي
صافي الدخل6.9 مليار US$الإهلاك والإطفاء+266 مليون US$تعديلات تشغيلية أخرى+2.1 مليار US$التدفق النقدي التشغيلي9.3 مليار US$
تسوية النقد من بداية الفترة إلى نهايتها
النقد في بداية الفترة3.2 مليار US$التدفق النقدي التشغيلي+9.3 مليار US$التدفق النقدي الاستثماري−341 مليون US$التدفق النقدي التمويلي−7.6 مليار US$النقد في نهاية الفترة4.5 مليار US$
9.3 مليار US$ − 216 مليون US$التدفق النقدي الحر 9.1 مليار US$
بيانات جسر التدفق النقدي
صافي الدخل
6,947,000,000 US$
التدفق النقدي التشغيلي الداخل
9,290,000,000 US$
الإهلاك والإطفاء
266,000,000 US$
تعديلات تشغيلية أخرى
2,077,000,000 US$
التدفق النقدي التشغيلي
9,290,000,000 US$
النقد المتاح
12,448,000,000 US$
النقد في بداية الفترة
3,158,000,000 US$
التدفق الاستثماري الخارج
341,000,000 US$
النفقات الرأسمالية
216,000,000 US$
أنشطة استثمارية أخرى
125,000,000 US$
التدفق التمويلي الخارج
7,615,000,000 US$
صافي إصدار الدين
385,000,000 US$
إعادة شراء الأسهم
1,000,000,000 US$
أرباح الأسهم المدفوعة
6,960,000,000 US$
أنشطة تمويلية أخرى
40,000,000 US$
النقد في نهاية الفترة
4,492,000,000 US$
التدفق النقدي الاستثماري
-341,000,000 US$
التدفق النقدي التمويلي
-7,615,000,000 US$
الإيرادات حسب القطاع التشغيليالحصة من إجمالي إيرادات 2025-12-31.
23.3 مليار US$إجمالي الإيرادات
الإيرادات حسب القطاع التشغيليالحصة
Smokeable Products20.5 مليار US$88%−3.4% على أساس سنوي
Oral Tobacco2.8 مليار US$12%+0.9% على أساس سنوي
All Other Segments5 مليون US$0%
المصدر: SEC EDGAR · تاريخ الإيداع 2026-02-25 · SEC EDGAR
بيانات توزيع الإيرادات: الإيرادات حسب القطاع التشغيلي
الإيرادات حسب القطاع التشغيلي
الإيرادات
الحصة
على أساس سنوي
Smokeable Products
20.5 مليار US$
88%
-3.4%
Oral Tobacco
2.8 مليار US$
12%
0.9%
All Other Segments
5 مليون US$
0%
—
الإيرادات والأرباحكيف يتحول حجم الأعمال إلى أرباح مُعلنة.
النقد والدينالسيولة المتاحة مقارنة بإجمالي الاقتراض.
توليد النقدالتدفق النقدي التشغيلي مقارنة بالتدفق النقدي الحر.
Altria Group Inc. (MO) trades at 11.9x forward earnings against a peer median of 15.2x. Its EV/EBITDA of 9.4x compares with a peer median of 10.7x. The comparison uses 4 peers: Target Corporation, Kimberly-Clark Corporation, Philip Morris International Inc. and Constellation Brands Inc., as of 2026-10-18.
§10 الصناعة والدورةEN
مرحلة الدورة
Contraction
The domestic tobacco industry operates in an advanced capital contraction phase characterized by negligible capital expenditures and zero physical capacity additions. Industry capex-to-revenue stands at -0.9% and industry capex-to-depreciation tracks at 0.71x. Altria expended only $216M on CapEx in FY2025 against $9,290M in operating cash flow and $23,279M in net revenues. Even with 2026 CapEx guided upward to $375M-$450M to fund the USSTC manufacturing facility consolidation, enterprise reinvestment remains exceptionally modest at ~2.0% of NOPAT.6
دورة صعودية
A favorable cycle scenario entails recovering consumer discretionary purchasing power, moderating combustible cigarette volume contraction toward -2.0% to -2.5% annually, and strict FDA enforcement against illicit disposable vapes that redirects volume back into authorized combustible brands and modern nicotine pouches. Under these conditions, premium brand equity remains fully intact, price realization easily compensates for volume decline, and modern oral pouch platforms experience rapid adoption across nationwide convenience and grocery store networks.
دورة هبوطية
An adverse cycle scenario is characterized by persistent consumer inflation, elevated living expenses, and depressed discretionary spending among adult nicotine consumers. This dynamic accelerates consumer trade-down from premium cigarettes into discount offerings, pushing industry discount share above 35%, while combustible volume declines accelerate beyond -5.0% trade-adjusted. Concurrently, weak regulatory enforcement allows unauthorized, illicit disposable e-vapor products to flood retail channels, displacing legal combustible and modern oral nicotine consumption.
الاتجاهات طويلة الأمد
الاتجاه
التأثير
ملاحظة
Secular Combustible Volume Decline
negative
Underlying U.S. combustible cigarette volume continues to contract at 4.0% to 4.5% annually adjusted for trade inventories, driven by smoking cessation, health awareness, and cross-category migration into smoke-free alternatives.
Rapid Expansion of Modern Oral Nicotine Pouches
positive
The modern oral nicotine pouch segment grew 8.1 percentage points YoY to represent 59.9% of the domestic oral tobacco market in Q2 2026, providing a vital long-term transition runway for on! and on! PLUS.
التموضع
Altria occupies the dominant profit pool in the U.S. tobacco industry, capturing $10,984M in Smokeable segment operating income in FY2025 and generating an adjusted operating margin of 64.9% in H1 2026. However, its pure domestic focus leaves it 100% exposed to U.S. regulatory scrutiny and secular cigarette contraction, unlike global peer Philip Morris International (PM), which generates 10.4% revenue growth and commands a $319.8B market cap. Altria's positioning is defensive, highly cash-generative, but fundamentally mature and transitioning slowly.7
§11 إدارة المراكزEN
حجم المركز
0-2% (Underweight). In accordance with our house Reduce rating and a 21.9% price premium to mid fair value ($61.61), overall portfolio exposure should be kept underweight (0-2%). Existing holders should trim into market strength, while income investors dependent on dividend cash flow should restrict holding size to an underweight posture with strict downside stops.
المخاطر
Risk management centers on capital preservation given the company's negative stockholders' equity and substantial total debt load. Investors must avoid averaging down above Fair value ($61.61) and enforce disciplined stops against sudden regulatory actions or volume contraction shocks.
شرائح الدخول
المستوى
إجراء
لماذا
$61.61 (Fair Value Parity)
Initiate exploratory tranche.
Eliminates the valuation premium, aligning entry with Fair value ($61.61) and securing attractive dividend yield support.
Substantial discount to $61.61 (Margin of Safety Zone)
Trading at an 11.89x forward P/E and a 21.9% premium to mid fair value ($61.61), the total return outlook is negative (-18.0% implied return), outweighing the ~5.9% dividend yield. Capital preservation demands avoiding new commitments.3
Income / Dividend Focused Investor
Hold
For income-mandated investors holding low-basis positions, the dividend ($4.44 per share annualized) is supported by $9.07B in free cash flow. However, holdings should be capped at underweight levels.5
Defensive / Risk-Conscious Investor
Avoid
With $24.58B in total debt, negative equity of -$2.67B, 42% revenue concentration in two distributors, and ongoing FDA menthol risk, risk-adjusted returns are unfavorable.3,7
§14 التوصية النهائيةEN
إجراء
تخفيض
We issue a Reduce recommendation on Altria Group Inc. (MO). Trading at $75.11 as of October 16, 2026, the stock trades at a 21.9% premium to mid intrinsic fair value of $61.61 (implied return of -18.0%). While Altria continues to extract robust free cash flow ($9,074M in FY2025) to support its ~5.9% dividend yield, the current valuation provides zero buffer against compounding combustible volume declines (-4.5% trade-adjusted in Q2 2026), discount trade-down to 33.8%, and smoke-free execution delays.3,4,5
Investors should capitalize on share price strength to reduce equity exposure toward an underweight posture. Capital is better deployed into defensive consumer assets where cash flow growth is supported by unit volume stability rather than pure pricing extraction in contracting categories.
§15ملاحظاتك
دوّن أطروحتك الاستثمارية وحجم مركزك وأسئلة المتابعة. تبقى على هذا الجهاز، ولا يراها أحد سواك.
ملاحظات خاصة
مرئية لك وحدك. محفوظة على هذا الجهاز.
لا أحرف
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-18 · Published 2026-10-18 · Provider-adjusted · cited for 3 figuresCited in شجرة قرارات الأرباح
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the Bear scenario, persistent macro inflation breaks Marlboro's pricing elasticity, forcing management to escalate promotional discounting to stem market share loss. An accelerated regulatory ban on menthol or flavor restrictions destroys significant combustible profit pools. Meanwhile, smoke-free diversification fails to achieve required scale, leaving the company vulnerable to terminal multiple de-rating. Operating cash flow declines, tightening coverage of the dividend and forcing a cessation of share repurchases, driving equity valuation down toward the $44.36 lower bound.
Within 12 months
Severe price elasticity deterioration and aggressive discount trade-down
In Q2 2026, discount cigarette industry share jumped 2.6 percentage points to 33.8% as adult consumers faced persistent inflation and strained discretionary income. If ongoing 7% annual Marlboro price hikes trigger an elasticity break, forcing Altria to expand promotional allowances to protect market share, consolidated operating margin would fall below 39.5% from 42.52% reported in FY2025, resulting in an estimated -18.2% fair value impact.4,6
FV impact
-2.1%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Terminal multiple de-rating under failed smoke-free diversification and illicit vape proliferation
Altria's current forward P/E is 11.89x. With NJOY ACE barred from importation in 2026, on! pouch share falling 1.7 pp to 14.4% in the pouch category, and illicit vapes continuing to displace combustible volume, the equity market would re-rate Altria as a structurally contracting melting pot, compressing its terminal P/E multiple by 20% to 9.0x or below, inflicting a -20.0% fair value impact.3,4,7
FV impact
-6.6%
Terminal multiple 20% lower
Trigger
Within 24 months
Macro interest rate shock and cost of capital normalization
The base valuation assumes computed moderate Ke of 7.46%, which incorporates a low raw beta of 0.4381. Normalizing beta to the sector average levered beta of 0.7943 pushes normalized Ke to 8.44%. If higher benchmark rates and debt refinancing costs on $24.58B in total debt push discount rates 200 bps above moderate Ke (crossing the 9.46% danger threshold), equity fair value declines by -22.8%.2,3
FV impact
-17.8%
Cost of capital 2 points higher
Trigger
Within 12 months
Marlboro Total Cigarette Retail Market Share
Share losses in Altria's flagship premium brand indicate that cumulative pricing hikes are eroding brand equity, forcing promotional discounting that compresses operating margins.
الحالي:39.5% in Q2 2026 (down 1.5 percentage points YoY from 41.0% in Q2 2025)
تنبيه إذاMarlboro total retail category share falling below 38.0%
03
Discount Cigarette Industry Retail Share
Consumer trade-down driven by cumulative inflation pressures adult smokers to abandon premium Marlboro, forcing Altria to expand margin-dilutive promotional allowances.
الحالي:33.8% of cigarette industry in Q2 2026 (up 2.6 percentage points YoY)
تنبيه إذاDiscount category industry retail share crossing 36.0%
04
Oral Nicotine Pouch Category Share (on!)
Failure of on! and on! PLUS to defend pouch market share against dominant competitors leaves Altria without a growing profit engine to offset declining traditional moist smokeless tobacco ($1,828M FY2025 OCI) and cigarettes.
الحالي:14.4% in Q2 2026 (down 1.7 percentage points YoY)
تنبيه إذاon! share of modern oral nicotine pouch category falling below 12.0%
Extreme wholesale concentration exposes Altria's route-to-market and finished goods cash collections to systemic counterparty risk across smokeable, oral, and e-vapor segments.
الحالي:42.0% of consolidated net revenues from top two wholesale distributors in FY2025 (23% and 19%)
تنبيه إذاOperational disruption, credit distress, or distribution fee renegotiation by either top distributor
Wide
Discretionary income strain driving adult smoker trade-down to discount cigarettes (discount share reached 33.8% in Q2 2026)
medium
12 to 24 months
Deploying a tiered portfolio approach, introducing Marlboro Cowboy Cut to retain value-sensitive premium smokers and leveraging Basic in discount.
FDA implementation of product standards banning menthol in combustible cigarettes and restricting pouch flavors
high
12 to 36 months
Engaging in scientific advocacy, preparing non-menthol alternative product portfolios, and pursuing PMTA authorizations for modified-risk alternatives.
Discounted forecast-period cash flows (19.51 US$) plus discounted terminal value (72.32 US$) minus signed per current share (12.72 US$) equals the 79.12 US$ lens value shown above. Negative net debt is , so subtracting it raises value.
FDA PMTA enforcement successfully eliminates illicit disposable vapes from retail shelves
Consolidated operating margin expands through smokeable pricing realization and supply chain efficiency.
Annual earnings per share growth accelerates above historical trend lines driven by share repurchases and margin expansion.
In the Bull scenario, adult consumer discretionary income recovers, curtailing discount trade-down. Regulatory enforcement against illicit disposable vapes redirects nicotine volume back into Marlboro and authorized oral nicotine pouches. Helix's national rollout of on! PLUS across 120,000 stores scales rapidly, turning the smoke-free segment into an accretive profit driver. Altria's FCF generation comfortably supports annual dividend increases and >$1B in annual share repurchases, justifying valuation near the top of the fair value range ($84.57).
المقياس:
on! Modern Oral Nicotine Pouch Category Share
الحالي14.4% in Q2 2026 (down 1.7 pp YoY, up 1.0 pp sequentially)
لماذا يهم
Measures the commercial scaling and competitive viability of Altria's primary smoke-free growth vehicle against category leaders.
04
المقياس:
NJOY ACE Commercial Re-Entry & FDA Enforcement
الحاليNJOY ACE barred from U.S. importation in 2026 under ITC exclusion orders; re-entry timing unannounced
لماذا يهم
Essential for determining whether Altria can participate in the largest reduced-risk nicotine category or face further asset write-downs.
05
المقياس:
Top Two Wholesale Distributor Concentration
الحاليTwo distributors represented 42% of consolidated net revenues in FY2025 (23% and 19%)
لماذا يهم
Represents extreme counterparty and working capital concentration risk across nationwide wholesale routes to market.
Altria's capital allocation framework prioritizes cash returns to shareholders, anchored by a progressive dividend commitment targeting an ~80% adjusted EPSpayout ratio. In H1 2026, Altria returned $3.9B to shareholders, comprising $3.6B in cash dividends and $335M in share repurchases (5.3M shares repurchased at an average price of $62.78). The company had $665M remaining under its $2.0B share repurchase authorization as of June 30, 2026. Capital expenditures remain highly disciplined ($216M in FY2025; guided to $375M-$450M in 2026 to support USSTC facility consolidation). Post-dividend discretionary excess cash flow tracks at ~$1.0B annually, which is allocated between opportunistic buybacks and debt management across $24,577M in total debt. Altria also holds valuable liquid stakes in Anheuser-Busch InBev ($8,896M equity investment value at Q2 2026) and Cronos Group.
Combustible cigarettes generate over 85% of total operating income, meaning any disruption to Marlboro's pricing elasticity directly threatens enterprise solvency and dividend coverage.
Wholesale distribution concentration introduces systemic counterparty risk.
In FY2025, two wholesale distributors accounted for 23% and 19% of consolidated net revenues, respectively, with no other customer exceeding 10%.
Any counterparty insolvency, inventory de-stocking, or contractual dispute by either major distributor poses an immediate threat to quarterly shipments and working capitalcash flow.
Reduced-risk business development has suffered chronic capital misallocation.
Altria recorded $903M in pre-tax impairment and exit charges in H1 2025, including an $873M goodwill impairment on e-vapor, followed by NJOY ACE being barred from importation in 2026.
M&A execution in reduced-risk alternatives has destroyed substantial balance-sheet equity, slowing smoke-free diversification and forcing reliance on internal on! pouch expansion.
Philip Morris International Inc.PM
السعر / القيمة العادلة
القيمة العادلة248.88 US$Report-date price184.73 US$
تاريخ التقييم
الميزة التنافسيةNone
بطاقة تقييم الاستثمار56 / 100
Constellation Brands Inc.STZ
السعر / القيمة العادلة
القيمة العادلة181.25 US$Report-date price122.64 US$
تاريخ التقييم
الميزة التنافسيةNarrow
بطاقة تقييم الاستثمار68 / 100
الهامش
MO
Altria Group Inc.
$125.4B
11.9x
6.1x
9.4x
—
—
TGT
Target Corporation
$70.1B
16.2x
0.7x
9.8x
26.4%
6.0%
KMB
Kimberly-Clark Corporation
$35.0B
14.3x
2.1x
11.7x
104.9%
19.0%
PM
Philip Morris International Inc.
$319.8B
22.3x
7.5x
20.3x
—
40.0%
STZ
Constellation Brands Inc.
$22.2B
10.9x
2.4x
9.6x
24.0%
33.6%
Proliferation of Illicit Disposable E-Vapor Platforms
negative
The persistent availability of unauthorized, flavored disposable e-vapor products continues to capture adult nicotine consumers, siphoning volume away from authorized combustible and smoke-free products.
Margin falling below 41.5% (vs 42.52% FY2025)
Re-evaluate Marlboro price elasticity durability and exit remaining equity exposure.
on! Category Share in Oral Nicotine Pouches
Category share falling below 12.5% (vs 14.4% in Q2 2026)
Remove smoke-free transition growth premium from valuation terminal multiple assumptions.
DSO extending by >5 days or credit deterioration at top two distributors
Hedge distribution counterparty exposure and re-examine short-term receivables liquidity.
The primary upside opportunity lies in Altria's commercial expansion of on! PLUS across 120,000 retail stores, which leverages existing retail distribution channels to convert adult smokers into smoke-free modern oral nicotine pouches and expand high-margin profit pools, supported by accelerated FDA enforcement against illicit disposable e-vapor products to stabilize category volume declines and drive terminal multiple expansion.
